Advanced Medical Isotope Corp. Pitch Deck (2017) Breakdown

Advanced Medical Isotope Corp. (OTC: ADMD) utilizes a 2017 investor presentation to pitch RadioGel, a brachytherapy device combining a liquid-to-solid hydrogel with Yttrium-90 phosphate particles. The company’s core strategy is a 'regulatory bridge': launching first in the veterinary market to generate revenue by January 2018, followed by international licensing for skin cancer. The deck highlights a significant total addressable market, claiming that treating just 10% of eligible pet cancers at $5,000 per therapy could yield $40M in annual revenue. While the technical and intellectual proper…

Key takeaways

• The company identifies as a late-stage developer of brachytherapy devices for both medical and veterinary applications (Slide 3).
• RadioGel technology uses Yttrium-90 phosphate, a high-energy beta emitter with a 2.7-day half-life, delivered via a temperature-sensitive hydrogel (Slide 5).
• The veterinary market strategy targets 78 million dogs and 86 million cats in the U.S., where cancer is a leading cause of death (Slide 9).
• AMI projects $1.5 billion in annual revenue from skin cancer by capturing 10% of the 3.3 million people affected in the U.S. (Slide 11).
• The growth strategy follows a tiered indication path: starting with skin cancer, moving to lymph nodes, and eventually liver/pancreas (Slide 13).
• Intellectual property is anchored by eight patents sublicensed from Battelle and trademark protection in 17 countries (Slide 15).
• The company utilizes a heavy-weight Medical and Scientific Advisory Board featuring MDs, DVMs, and PhDs to validate the technology (Slide 17).
• A primary corporate goal stated in the highlights is to uplist from the OTC (ADMD) to a senior exchange like NASDAQ or NYSE MKT (Slide 19).

Frequently asked questions

What is the primary product being pitched?

The product is RadioGel, a brachytherapy device. It consists of a hydrogel that is liquid at room temperature but solidifies at body temperature, locking Yttrium-90 phosphate particles directly into a tumor. This allows for high-dose radiation with minimal collateral damage to healthy tissue due to the short travel distance of the radiation and the 2.7-day half-life of the isotope.

How does the company plan to generate revenue quickly?

AMI plans to bypass the lengthy human clinical trial timeline by first entering the veterinary market. Slide 9 indicates they expected revenue to begin by January 2018 from private veterinary clinics. They also planned to generate international licensing revenue from skin cancer applications in early 2018, leveraging the lower cost and shorter approval path of a medical device compared to a drug.

What is the status of their intellectual property?

According to Slide 15, AMI has secured rights to eight patents through a sublicensing agreement with Battelle. They also claim proprietary intellectual property regarding production procedures, test data, and advanced product development (resorption time and imaging). Their trademark protection extends to 17 countries, providing a global defensive moat for the brand.

Who is leading the scientific validation of the technology?

The company relies on a multi-disciplinary advisory board. This includes Dr. Barry D. Pressman (Chairman of the Medical Advisory Board), Dr. Alan E. Waltar (Chairman of the Scientific Advisory Board), and Dr. Alice Villalobos (Chair of the Veterinary Medicine Advisory Board). The board also includes specialists in radiation oncology and nuclear physics to cover the technical breadth of the product.

What are the projected market sizes for their target indications?

For the veterinary market, they estimate a $40M annual revenue opportunity based on a 10% penetration rate. For the human skin cancer market, they cite 5.4 million cases per year in the U.S. and project a $1.5 billion annual revenue stream if they capture 10% of the market at a $5,000 price point per therapy.

Advanced Medical Isotope Corp. pitch deck: the facts

Company

Advanced Medical Isotope Corp.

Year

2017

Stage

Late-stage development / Public (OTC)

Slides

20

Sector

Biotechnology / Medical Devices

Deck type

Investor Presentation

Outcome

Active on OTC (as Vivos Inc. / RDGL)

Headquarters

Kennewick, Washington, USA

Advanced Medical Isotope Corp. pitch deck PDF

The full Advanced Medical Isotope Corp. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Advanced Medical Isotope Corp. (later Vivos Inc.) pitch deck was used for

This deck is an **August 2017 OTC investor presentation** for Advanced Medical Isotope Corporation (ticker ADMD), a later‑stage public microcap developing the RadioGel yttrium‑90 hydrogel brachytherapy device for cancer in humans and animals. It positions a strategic focus on the **IsoPet veterinary division** to generate near‑term revenue from private animal clinics and international licensing while continuing FDA interactions for human indications. The company emphasizes that the FDA has ruled RadioGel a device for humans and is pursuing clarification that the same device classification applies to animal use, to avoid pre‑market approval for pet therapy and shorten regulatory timelines. Being already public on the OTC market, the deck serves more as a **capital markets and investor‑relations fundraising tool** (supporting equity financing and eventual uplisting) than a classic private‑round pitch.

Business model: Radiation oncology medical device company developing **yttrium‑90-based brachytherapy / precision radionuclide therapy devices** that deliver radiation directly inside solid tumors in humans and animals using an injectable hydrogel (RadioGel for humans, IsoPet for animals). The animal therapy (IsoPet) is used to penetrate solid tumors in veterinary oncology while limiting damage to surrounding hea

Headquarters: Kennewick/Richland, Washington, United States (e.g., historical SEC filings and later profiles list Kennewick/Richland WA addresses for Advanced Medical Isotope Corp./Vivos Inc.).

Industry: Biotechnology / Medical Devices; specifically radiation oncology and radiopharmaceutical / radionuclide therapy devices.

What happened after the Advanced Medical Isotope Corp. (later Vivos Inc.) deck

Following this 2017 OTC investor deck, Advanced Medical Isotope Corporation proceeded with its yttrium‑90 hydrogel brachytherapy strategy, rebranding as **Vivos Inc.** in December 2017 and continuing development of RadioGel for human oncology and IsoPet for veterinary oncology. The company has highlighted FDA device classification for RadioGel, an LSDF grant supporting product development, and ong

• The company, originally named Advanced Medical Isotope Corporation, formally began operating as **Vivos Inc.** on **Dece
• The FDA recommended that the same yttrium‑90 hydrogel product be marketed as **IsoPet** for veterinary use and **RadioGe
• The company was awarded a **$250,000 Proof of Concept grant from the Washington State Life Sciences Discovery Fund (LSDF

What the Advanced Medical Isotope Corp. (later Vivos Inc.) deck got right

• Clear and differentiated technical value proposition. The deck presents a **distinctive technical platform**: an injectable hydrogel that is liquid at room temperature and solidifies at body temperature, locking yttrium‑90 phosphate particles within the tumor to deliver a high‑dose, short‑range beta radiation treatment, which is clearly differentiated from conventional brachytherapy seeds.
• Strategic use of veterinary market for near‑term revenues. AMI positions **IsoPet veterinary oncology** as a near‑term commercialization avenue, with expected revenues by January 2018 and international licensing in early 2018, supported by ongoing studies at university veterinary programs, which provides a credible path to earlier revenue ahead of human approvals.
• Credible advisory and clinical network. The presentation emphasizes a **strong Medical Advisory Board and Mayo Clinic involvement**, citing more than 125 years of combined experience and input from Mayo Clinic doctors, which bolsters perceived clinical credibility and suggests access to expert guidance for indication selection and trial design.
• Favorable device classification by FDA. The deck underscores that the **FDA has ruled RadioGel a device** for humans, implying a potentially more favorable regulatory and economic pathway than a drug, with lower costs and shorter approval timelines for devices, which is attractive to investors sensitive to regulatory risk.
• Transparent snapshot of public‑market status. Slides provide **concrete stock statistics** (price, market cap, shares outstanding, float, 52‑week range) and explicitly state the OTC listing and ticker (ADMD), allowing investors to quickly contextualize valuation and liquidity at the time of the presentation.
• Large potential indication breadth and market optionality. The deck’s narrative integrates human and animal oncology applications and lists multiple potential cancer indications (skin cancer first, then others), showcasing **broad therapeutic optionality** and a large potential addressable market for the core Y‑90 hydrogel technology.

What could have been stronger

• No explicit round size, security terms, or use‑of‑funds breakdown. The deck does not specify **how much capital is being raised, what type of securities (common, preferred, units) are offered, or explicit use‑of‑funds allocations**, despite functioning as an investor presentation for a microcap public company; investors cannot see the funding target or dilution implied.
• Limited evidence of commercial traction or economic model. While the slides repeatedly emphasize anticipated IsoPet revenues by January 2018 and international licensing income in early 2018, there is **no historical revenue data, no signed customer contracts, no pipeline metrics, and no unit economics**, making it hard to assess commercial traction or validate the near‑term revenue story.
• Regulatory strategy and timelines not fully articulated. The deck leans heavily on the statement that the **FDA ruled RadioGel is a device**, but provides limited detail on the regulatory pathway (e.g., 510(k) vs. PMA), specific interactions with FDA, or timelines for human indications beyond a high‑level aspiration, leaving regulatory risk largely unquantified.
• Sparse financial disclosure for a public microcap. Although the company is already public on the OTC market, the presentation offers only a brief snapshot of market cap, share price, and float without **balance sheet data, cash burn, or historical financings**, so prospective investors cannot easily gauge runway, prior dilution, or capital structure risk.
• Many potential indications with limited prioritization and supporting data. The slides present an extensive list of potential cancer indications (skin, liver, prostate, head and neck, etc.), but offer **little prioritization or data for each indication**, which may suggest strategic diffusion and make it difficult for investors to understand the near‑term clinical focus beyond skin cancer and selected veterinary sarcomas.

How an investor would read this deck

What draws attention

• Clarify the **regulatory status and pathway** for RadioGel in humans (device classification details, required studies, expected timeline) and confirm whether the same device classification applies to IsoPet animal use without pre‑market approval.
• Assess the **commercial readiness of IsoPet**, including veterinary clinic interest, university trial progress, and concrete steps to convert demonstration projects into paying customers by the stated 2018 targets.
• Understand the company’s **capital markets plan**, including any planned OTC financings, structure of raises tied to this deck, and specifics of the proposed uplisting to NASDAQ or NYSE MKT (listing requirements, timeline, and prerequisites).
• Evaluate the **technical differentiation** of the yttrium‑90 hydrogel platform versus competing brachytherapy or radionuclide treatments, focusing on dosimetry, safety, and comparative efficacy data referenced by the Mayo Clinic and other advisors.
• Review **governance and team strength**, including the depth of the medical advisory board, Mayo Clinic involvement, and prior execution track record in bringing radiopharmaceutical devices through FDA processes.

Risks that stand out

• **Regulatory and classification risk** if FDA requirements for the human device prove more extensive than anticipated, or if animal use cannot proceed without pre‑market approval, potentially delaying both IsoPet and RadioGel commercial timelines.
• **Execution risk in commercializing IsoPet**, given dependence on university demonstration projects, the need to convert academic results into private clinic adoption, and limited disclosed evidence of signed customers or reimbursement pathways.
• **Microcap public‑market risk**, including share price volatility, potential dilution from future OTC financings, and limited liquidity, as highlighted by low share price and small market cap in the deck’s stock statistics.
• **Clinical and safety risk** inherent to localized high‑dose beta radiation in solid tumors, especially in sensitive locations (e.g., liver, head and neck, ocular melanoma), where off‑target effects or complications could impact adoption.
• **Competitive and technology risk** if other radionuclide or brachytherapy innovations for non‑resectable solid tumors reach market with stronger efficacy or safety data before RadioGel/IsoPet achieves broad regulatory clearance and commercial traction.

Questions this deck invites

• What specific **FDA interactions and submissions** (e.g., pre‑submission, IDE, 510(k), or other device filings) have occurred for RadioGel, and what formal feedback or milestones have been achieved to date?
• Which **university veterinary trials** (Washington State, UC Davis, Colorado State, University of Missouri, and others) have been completed or are ongoing, and what are the key efficacy and safety outcomes for IsoPet in feline/canine sarcom
• What are the company’s **current revenue, cash balance, and monthly burn**, and how much capital is required to reach defined inflection points such as first recurring IsoPet revenues, completion of pivotal animal studies, or human skin can
• How does the yttrium‑90 hydrogel platform compare in **cost, safety profile, and clinical outcomes** to alternatives like existing brachytherapy seeds, external beam radiation, or other radionuclide therapies for the same indications?
• What is the company’s **IP position**, including patents, exclusive licenses, and any encumbrances, and how long is the remaining life on key patents covering the hydrogel delivery system and Y‑90 formulation?

What founders can take from the Advanced Medical Isotope Corp. (later Vivos Inc.) deck

• A **clear technology narrative**—explaining how a hydrogel transitions from liquid at room temperature to solid at body temperature and traps Y‑90 particles within a tumor—can make a complex radiopharmaceutical concept accessible and memorable to investors.
• Positioning a **veterinary application (IsoPet) as a near‑term revenue bridge** while human indications progress through FDA pathways illustrates how adjacent markets can be used strategically to de‑risk development stories.
• Including **specific advisory board credentials and Mayo Clinic involvement** can strengthen perceived credibility for novel oncology devices, provided the roles and contributions are clearly described.
• Even for a public microcap, investors expect **basic financial and funding details** (raise amount, use of proceeds, cash runway); their absence in an investor deck becomes a noticeable gap that can undermine confidence.
• Clearly stating that **FDA classified the product as a device** is powerful, but investors still need to see the concrete regulatory path and milestones; high‑level classification alone is not enough to fully address risk.
• Listing a wide range of future indications can showcase upside, but without prioritization and supporting data it can appear unfocused; focusing the deck on a small number of well‑supported lead indications makes the story more investable.

Advanced Medical Isotope Corp. (later Vivos Inc.) pitch deck: common questions

What does Advanced Medical Isotope Corp. (AMI) do?

Advanced Medical Isotope Corporation (later renamed Vivos Inc. in December 2017) is a radiation oncology medical device company that develops **yttrium‑90‑based hydrogel brachytherapy devices** to treat non‑resectable solid tumors in humans and animals. Its flagship human product is RadioGel, and the veterinary product line is branded IsoPet.

What is RadioGel and how is it supposed to work?

RadioGel is described as an injectable **hydrogel liquid that is liquid at room temperature and solidifies at body temperature**, locking in tiny yttrium‑90 phosphate particles within the tumor so they can deliver a very high, localized beta radiation dose with minimal collateral damage and a short (2.7‑day) half‑life. According to company materials and later profiles, RadioGel is intended for precision radionuclide therapy of non‑resectable solid tumors in human oncology, while the same platform under the IsoPet name serves veterinary oncology.

What is IsoPet?

IsoPet is AMI’s **veterinary oncology brand** for its yttrium‑90 hydrogel platform, used to treat solid tumors in animals. The deck states the company expects revenue from IsoPet by January 2018 or earlier, targeting private veterinary clinics and supported by university‑based studies in feline and canine sarcomas and other tumor types.

What were AMI’s key stock statistics around the time of this deck?

The 2017 investor presentation shows that AMI common stock traded on the **OTC market under ticker ADMD**, with a share price of about **$0.10**, market cap around **$5.0 million**, approximately **50.1 million shares outstanding**, and a 52‑week range of **$0.05–$1.00**, based on data as of July 18, 2017.

What happened to Advanced Medical Isotope Corp. after this 2017 deck?

Public filings indicate that the company changed its name from Advanced Medical Isotope Corporation to **Vivos Inc.** and began operating under that name on **December 28, 2017**. Later profiles describe Vivos Inc. as continuing the same yttrium‑90 RadioGel/IsoPet device strategy for precision radionuclide therapy in humans and animals.

Sources

Funding and outcome facts on this page were researched on 2026-08-21 from the pages below.

• Mayo Clinic Doctor Joins Advanced Medical Isotope Corporation's...
• About Vivos Inc.
• Advanced Medical Isotope Corp. Presentation | PPTX - Slideshare
• About Vivos Inc (RDGL) - Investing.com NG
• Advanced Medical Isotope (RDGL) Stock Price, News & Analysis
• Vivos Inc. (RDGL) Company Profile & Facts - Yahoo Finance
• Vivos Inc.
• Filing Detail

Advanced Medical Isotope Corp. pitch deck slides

What each slide of the Advanced Medical Isotope Corp. pitch deck says

Slide 2

ADVANCED MEDICAL 150T0PE This Overview contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will" "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, AMI's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partner…

Slide 3

ADVANCED MEDICAL 150T0PE Advanced Medical Isotope Corporation (AMI) is in the late-stage development of a brachytherapy device for medical and veterinary cancer treatment applications. brach-y-ther-a-py /braké THerapé/ the treatment of cancer by the insertion of radioactive implants (isotopes) directly into the tissue — inside or next to the treatment area AMl is led by a competent team with impressive credentials that believes in strategic partnerships with national labs, universities and private corporations. Plans to generate near-term revenue from veterinarian clinics and international licensing while pursuing FDA approval for multiple cancer indications and offering the potential econo…

Slide 4

ADVANCED MEDICAL 150T0PE Provide a new potent brachytherapy tool for the treatment of cancers in humans and animals that will be very effective in improving the lives of these patients. Generate near-term revenue from veterinarian clinics and international licensing while pursuing FDA approval for multiple cancer indications. ADVANCED MEDICAL ISOTOPE CORPORATION

Slide 5

ADVANCED MEDICAL 150T0PE Next-generation radiopharmaceutical therapeutic device. O The Gel delivery vehicle is hydrogel = Liquid at room temperature = Solidifies at body temperature and locks in the particles Q4 The Particle is Yttrium-90 phosphate = Very small size insoluble particles — Perfuses within the tumor = Highest energy beta emitter — Delivers very high dose to the tumor = Radiation travels a short distance — Minimal collateral damage to healthy tissue outside the target region = 2.7 day half-life — Only 5% of radiation left after 10 days ADVANCED MEDICAL ISOTOPE CORPORATION

Slide 6

ADVANCED MEDICAL 150T0PE = Expect revenue from IsoPet by January 2018 or earlier = nternational licensing revenue expected in early 2018 = Strong leadership and world-class Medical Advisory Board = Plan to uplist to senior exchange (NASDAQ or NYSE MKT) = Partnerships with leading national labs, universities, and private corporations = Optimization of proprietary production process complete = FDA ruled that our product is a device - attractive drug economics, with lower costs and shorter approval pathway of device = Exclusive license and extensive intellectual property protections ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD

Slide 8

ADVANCED MEDICAL 150T0PE FDA ruled that RadioGel ™ is a device for humans. We are now confirming that this applies to animals to insure that no pre-market approval is required for pet therapy. Testing at leading university veterinary programs to demonstrate therapy across multiple indications: WASHINGTON STATE & UCDAVIS Clprado NIVERSITY . s . s Qu University of Missouri Pk b e University Feline Sarcoma Canine Sarcoma Prostate Cancer Feline Oral Cancer Equestrian Sarcoma Liver Cancer Mast Cell Skin Cancer Program guided by Dr. Alice Villalobos — Chair of the Veterinary Medical Advisory Board ADVANCED MEDICAL ISOTOPE CORPORATION

Slide 10

O Medical Advisory Board = More than 125 years combined experience = Input from Mayo Clinic doctors Q Selection criteria = Effective in killing cancer cells = Notable advantages over existing therapies = Can be profitably embraced by the medical community QSkin cancer selected for first Indication for Use ADVANCED MEDICAL ISOTOPE CORPORATION Skin cancer Involved lymph nodes Liver Pancreas Head and neck Bladder Ocular melanoma Rectal Non-dendritic brain Gynecological Spinal Sino-nasal Oropharyngeal Recurring esophageal Base of tongue Localized prostate Breast cavity resectomy Anaplastic thyroid OTC: ADMD 10

Slide text above is read directly from the Advanced Medical Isotope Corp. deck PDF embedded on this page.

Related fundraising guides (24)

• api.video Pitch Deck Teardown: A Developer-First Approach to $12M Series A
• Yelp Pitch Deck Teardown: A Post-IPO Growth Story Focused on Local Ad Dominance
• Green Li-ion Pitch Deck Teardown: A Masterclass in Supply Chain Disruption for Battery Recycling
• Clutch Wallet Pitch Deck Teardown: A $800k Pre-Seed Bet on Web3 Inclusivity
• Alphin Pitch Deck Teardown: A $6M Series A Masterclass in Local SMB Digitization
• Viso Pitch Deck Teardown: A 42-Slide Masterclass in Computer Vision Infrastructure
• Florence Pitch Deck Teardown: Scaling a Healthcare Staffing Marketplace to £9bn Market Potential
• Circ Pitch Deck Teardown: Solving the Polycotton Recycling Gap with Hydrothermal Tech
• AgomAb Therapeutics Pitch Deck Teardown: A Masterclass in Biotech Pipeline Visualization
• Martian Pitch Deck Teardown: A $9M Seed Masterclass in LLM Orchestration and Interpretability
• Evy Pitch Deck Teardown: A 10-Slide Masterclass in Embedded Insurance Minimalism
• Calico Pitch Deck Teardown: A 6-Slide Masterclass in Supply Chain Simplification
• Aceiss Pitch Deck Teardown: A Masterclass in Team Credibility and Problem Framing
• Include Pitch Deck Teardown: Scaling Smart City Infrastructure Through Global Distribution
• Everphone Pitch Deck Teardown: A $200M Masterclass in Unit Economics and Circularity
• Bravo Sierra Pitch Deck Teardown: Leveraging Military Community for CPG Scale
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• EcoVadis Pitch Deck Teardown: A Masterclass in Growth-Stage Market Dominance
• BetterManager Pitch Deck Teardown: A $16M Series A Built on Traction and Google Pedigree
• Connected Analytics Pitch Deck Teardown: Solving the Cash-Loyalty Gap in Africa
• Hint Health Pitch Deck Teardown: Scaling Direct Primary Care Infrastructure
• Domino Data Lab Pitch Deck Teardown: A Masterclass in Enterprise Social Proof
• Avo Pitch Deck Teardown: A B2B2C Strategy for Last-Mile Logistics Dominance

Decks from the same year (1)

• 2017 pitch deck examples

Decks from the same region (1)

• US pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with A

More pitch deck teardowns (16)

• Slamby Pitch Deck Teardown: A Masterclass in Minimalist B2B Data Classification
• Amodo Pitch Deck Teardown: A Case Study in Visual-First Connected Car Telematics
• AdKiosks Pitch Deck Teardown: A 2017 Vision for Transactional Display Advertising
• Adobe × Figma Pitch Deck Breakdown: The $20B Strategic Rationale for a Failed Acquisition
• Adobe × Macromedia Acquisition Pitch Deck Breakdown: The $3.4B Strategic Consolidation
• AdPushup Pitch Deck Breakdown: A Case Study in Pre-Seed Traction and AdTech Optimization
• AdsGency Pitch Deck Teardown: A $12M Seed Story Built on Rapid Revenue Scaling
• Advanced Emissions Solutions Pitch Deck Teardown: Navigating a Post-Restructure Turnaround
• Adventr Pitch Deck Teardown: Proving 1300% Engagement Gains in Interactive Video
• Adventure Bucket List Pitch Deck Breakdown: A B2B2C Play for Tourism Digitization
• Adventureclicknblog Pitch Deck Teardown: A Content-First Marketplace Strategy
• AdVolve Media Pitch Deck Teardown: A Hardware-Enabled Ad Network for Captive Audiences
• Ady Pitch Deck Teardown: Navigating Post-Crisis Growth in the Chinese Dairy Market
• Broadwind Energy Pitch Deck Teardown: Navigating Industrial Headwinds and Wind Backlogs
• AEGIS Pitch Deck Teardown: A Hardware-First Approach to Personal Safety Wearables
• AERA Health Pitch Deck Teardown: A $4.3M Masterclass in Longevity Market Positioning

Recently published pitch deck teardowns (12)

• Code Four Pitch Deck Breakdown: Automating Police Paperwork with AI-Driven Workflows
• Coinalytics Pitch Deck Breakdown: A Minimalist Approach to Blockchain Intelligence
• CodeSandbox Pitch Deck Breakdown: Moving the IDE to the Collaborative Cloud
• Common Room Pitch Deck Breakdown: Defining the Community Intelligence Category
• Compass Pathways Pitch Deck Breakdown: Clinical Data and Regulatory Roadmaps for Psilocybin
• CommandBar Pitch Deck Breakdown: A Masterclass in Thesis-Driven Seed Fundraising
• Connected2me Pitch Deck Breakdown: Scaling Anonymous Messaging to 2.7M Users
• CollateralEdge Pitch Deck Breakdown: Solving the Middle Market Debt Gap with Risk Transfer
• ConcertWithMe Pitch Deck Breakdown: A High-Traction, Low-Professionalism Seed Deck
• Concept Ventures Pitch Deck Breakdown: A Founder-First Approach to Pre-Seed VC
• ConextVR Pitch Deck Breakdown: A 'Rocket Ride To Success' Traction Slide With No Numbers On It
• Clearbanc Pitch Deck Breakdown: Redefining Growth Capital for the DTC Era

Fundraising library · Pitch deck examples · Investor directory · Founder database